CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Moses laser enucleation of prostateprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04263987
NCT04263987Phase 3Completed
CompareCT.gov

A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial

Vanderbilt University Medical Center·interventional·Posted Feb 11, 2020·Updated Mar 31, 2022

In Brief

A Phase 3 clinical trial evaluating Moses laser enucleation of prostate for Benign Prostatic Hyperplasia. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for the treatment of benign prostatic hypertrophy (BPH). New laser technologies such as the Moses Pulse laser system provide for improved energy delivery which may decrease blood loss and operative time. We seek to evaluate Moses technology for enucleation of the prostate in the setting of BPH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 11, 2020
Enrollment StartJan 1, 2020
Primary CompletionDec 30, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.4 years ago

Interventions

Moses laser enucleation of prostateprocedure

Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time